Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
N/A
2(40.0%)
5Total
Phase 2(3)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00146562Phase 2Completed

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

Role: lead

NCT00121134Not ApplicableCompleted

Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer

Role: lead

NCT00670982Phase 2Completed

Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer

Role: lead

NCT00136539Phase 2Completed

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

Role: lead

NCT00308178Not ApplicableCompleted

Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer

Role: lead

All 5 trials loaded